The European Commission has been overruled in a dispute over the authorisation of an orphan medicine, in a case that further clarifies the ‘well-established medical use’ criteria for approving new drugs for marketing in Europe. ---Subscribe to MedNous to access this article--- Company News IPR & Legal Regulation & Policy
